๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Is staging laparotomy necessary in pediatric hodkin's disease? A pediatric oncology group study

โœ Scribed by Nancy Price Mendenhall; Alan B. Cantor; Jessie Ternberg; Michael A. Weiner; Faith Kung; Brigid G. Leventhal

Publisher
Elsevier Science
Year
1992
Tongue
English
Weight
155 KB
Volume
24
Category
Article
ISSN
0360-3016

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Cisplatin in recurrent pediatric brain t
Cisplatin in recurrent pediatric brain tumors A pog phase II study a pediatric oncology group study
โœ Charles L. Sexauer; Atiya Khan; Peter C. Burger; Jeffrey P. Krischer; Jan Van Ey ๐Ÿ“‚ Article ๐Ÿ“… 1985 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 417 KB ๐Ÿ‘ 2 views

Forty-six evaluable pediatric patients with primary recurrent brain tumors resistant to standard therapy were treated with cisplatin, 60 mg/m\*/day, X2 days every 3 to 4 weeks, to study the efficacy and toxicity of this drug. Complete and partial responses, documented by computed tomography (CT) sca

Phase I trial of trimetrexate in pediatr
Phase I trial of trimetrexate in pediatric solid tumors: A pediatric oncology group study
โœ Pappo, Alberto S. ;Vats, Tribhawan ;Williams, Thomas E. ;Bernstein, Mark ;Kamen, ๐Ÿ“‚ Article ๐Ÿ“… 1993 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 283 KB

## Abstract Trimetrexate (TMTX), a lipophilic antifol, was evaluated in a Pediatric Oncology Group (POG) Phase I trial in children with refractory solid tumors. TMTX was administered intravenously daily ร— 5 every three weeks. Starting dose was 6.4 mg/m^2^/day. Dose was escalated by 20% until the ma

Treatment of osteosarcoma with ifosfamid
Treatment of osteosarcoma with ifosfamide: Comparison of response in pediatric patients with recurrent disease versus patients previously untreated: A pediatric oncology group study
โœ Harris, Michael B. ;Cantor, Alan B. ;Goorin, Allen M. ;Shochat, Stephen J. ;Ayal ๐Ÿ“‚ Article ๐Ÿ“… 1995 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 523 KB

## Abstract This study was designed to test if the activity of a phase II agent, ifosfamide, would have been underestimated if it was tested exclusively in a population of children and young adults with recurrent osteosarcoma. The response rate to ifosfamide was compared in patients younger than 30